InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
Portfolio Pulse from
InflaRx's stock (IFRX) increased by 8% following the European Commission's conditional approval of Gohibic, a drug for treating COVID-19-induced ARDS in adults.
January 16, 2025 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
InflaRx's stock rose by 8% due to the European Commission's conditional approval of Gohibic for treating COVID-19-induced ARDS in adults.
The conditional approval by the European Commission is a significant regulatory milestone for InflaRx, likely boosting investor confidence and driving the stock price up. The 8% increase reflects positive market sentiment towards the potential of Gohibic in treating COVID-19-induced ARDS.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100